Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 3/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869650 | 0.93 | PIK3CD (0.47) | PRKCQPIK3CAPIK3CDPIK3CBKDM1A | |
| SCHEMBL30869756 | 0.92 | PIK3CG (0.49) | PIK3CGPIK3CAPIK3CDPIK3CBKDM1A | |
| SCHEMBL30869877 | 0.83 | PIK3CD (0.48) | PRKCQPIK3CAPIK3CDPIK3CBTLR8 | |
| SCHEMBL30869587 | 0.83 | PIK3CG (0.41) | PIK3CGPIK3CAPIK3CDPIK3CBKDM1A | |
| SCHEMBL30869713 | 0.82 | PIK3CA (0.36) | PIK3CGPIK3CAPIK3CDKDM1A | |
| SCHEMBL30869729 | 0.78 | PIK3CG (0.48) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL32682887 | 0.77 | EGFR (0.52) | PRKCQPIK3CAKDM1A | |
| SCHEMBL30869758 | 0.75 | KDM1A (0.47) | PIK3CAKDM1A | |
| SCHEMBL30869495 | 0.73 | NUDT1 (0.39) | PRKCQTLR8TLR7NUDT1 | |
| SCHEMBL30869668 | 0.73 | NUDT1 (0.39) | PRKCQTLR8TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | PRKCQ 96/4885PIK3CG 159/4885PIK3CA 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.